Literature DB >> 3877052

Cyclosporine augments receptor-mediated cellular Ca2+ fluxes in isolated hepatocytes.

C V Nicchitta, M Kamoun, J R Williamson.   

Abstract

The immunosuppressive agent, cyclosporine, has been found to augment receptor-stimulated calcium fluxes in isolated hepatocytes. After treatment of Quin 2-loaded hepatocytes with cyclosporine, both the amplitude and duration of the vasopressin-induced rise in the cytosolic free Ca2+ are increased. These effects are dependent upon the concentration and time of exposure of the cells to cyclosporine. Cyclosporine increases both 45Ca2+ influx across the plasma membrane and the cellular calcium content. The total cellular magnesium, sodium, and potassium contents are not affected by cyclosporine. However, cyclosporine treatment, per se, has no apparent effect on the cytosolic free Ca2+ concentration as assayed by Quin 2 fluorescence. The increase in total cell calcium is associated with progressive increases in the calcium content of the endoplasmic reticular and mitochondrial calcium pools. The vasopressin-induced net efflux of Ca2+ from hepatocytes was 2-fold greater after treatment with 10 micrograms/ml cyclosporine for 10 min, but the lag time prior to the onset of Ca2+ efflux was not affected. These results are interpreted on the basis of cyclosporine having a primary effect on increasing the permeability of the plasma membrane to Ca2+, thereby leading to an increase of the calcium content of the hormone-sensitive intracellular calcium pool.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877052

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Cyclosporin A inhibits phorbol ester-induced activation of superoxide production in resident mouse peritoneal macrophages.

Authors:  M D Chiara; F Bedoya; F Sobrino
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

2.  In vitro effects of cyclosporine and FK 506 on the renal cortex.

Authors:  S J Prasad; J McCauley; G Salama; T E Starzl; S A Murray
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Indium-111 myosin-specific antibodies and technetium-99m pyrophosphate in the detection of acute cardiac rejection of transplanted hearts: studies in a heterotopic rat heart model.

Authors:  K Takeda; K Ueda; U Scheffel; H Ravert; N D LaFrance; W A Baumgartner; B A Reitz; A Herskowitz; H N Wagner
Journal:  Eur J Nucl Med       Date:  1991

4.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Effects of cyclosporins and transforming growth factor beta 1 on thyroid hormone action in cultured fetal rat limb bones.

Authors:  P Lakatos; P H Stern
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

6.  Uncoupling of Ca2+ transport ATPase in muscle and blood platelets by diacylglycerol analogues and cyclosporin A antagonism.

Authors:  C M Cardoso; V M Rumjanek; L De Meis
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

7.  Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669.

Authors:  Y Prinsloo; C E van Rensburg; R van der Walt; R Anderson
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

8.  Liver injury from cyclosporine A.

Authors:  C Kassianides; R Nussenblatt; A G Palestine; S D Mellow; J H Hoofnagle
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

9.  Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro.

Authors:  L K McCauley; T J Rosol; C C Capen
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

10.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.